KRAS and non-small cell lung carcinoma: However, while Gianoncelli et al. observed no significant differences between KRAS+ and non-KRAS NSCLC patients in terms of progression-free or overall survival [184], Kauffmann-Guerrero et al. reported a positive outcome for KRAS mutations in response to immune checkpoint inhibitors [185].